keyword
MENU ▼
Read by QxMD icon Read
search

Nivolumab

keyword
https://www.readbyqxmd.com/read/28726813/lung-cancer-frontline-nivolumab-checkmate-026-ends-in-stalemate
#1
David Killock
No abstract text is available yet for this article.
July 20, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28725430/acute-interstitial-nephritis-after-sequential-ipilumumab-nivolumab-therapy-of-metastatic-melanoma
#2
Lea Bottlaender, Anne-Laure Breton, Louis de Laforcade, Frederique Dijoud, Luc Thomas, Stephane Dalle
BACKGROUND: The anti-Programmed Death receptor 1 (anti-PD-1) antibodies nivolumab and pembrolizumab are new treatments in metastatic melanoma. Immunotherapies are best known to be responsible for thrombotic microangiopathy. However, immune interstitial nephritis has been described in a patient treated by nivolumab and ipilimumab concomitantly, and three cases of granulomatous interstitial nephritis have been reported with ipilimumab monotherapy. We report herein a case of acute interstitial immune nephritis in a patient treated with nivolumab after ipilimumab for pulmonary metastatic melanoma...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28719585/immunotherapy-reality-check-for-nivolumab-in-advanced-stage-melanoma
#3
Diana Romero
No abstract text is available yet for this article.
July 18, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28719552/immune-checkpoint-inhibitors-in-organ-transplant-patients
#4
Adam S Kittai, Hayden Oldham, Jeremy Cetnar, Matthew Taylor
Modulation of T-cell activity through blockade of coinhibitory molecules has revolutionized the treatment of various malignancies. Several immune checkpoint inhibitors are currently Food and Drug Administration approved which target various coinhibitory pathways including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 receptor (PD-1), and programmed cell death ligand-1. Clinical trials that lead to the Food and Drug Administration approval of these agents often excluded patients with an organ transplant...
July 17, 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/28716106/acute-interstitial-nephritis-after-sequential-ipilumumab-nivolumab-therapy-of-metastatic-melanoma
#5
Lea Bottlaender, Anne-Laure Breton, Louis de Laforcade, Frederique Dijoud, Luc Thomas, Stephane Dalle
BACKGROUND: The anti-Programmed Death receptor 1 (anti-PD-1) antibodies nivolumab and pembrolizumab are new treatments in metastatic melanoma. Immunotherapies are best known to be responsible for thrombotic microangiopathy. However, immune interstitial nephritis has been described in a patient treated by nivolumab and ipilimumab concomitantly, and three cases of granulomatous interstitial nephritis have been reported with ipilimumab monotherapy. We report herein a case of acute interstitial immune nephritis in a patient treated with nivolumab after ipilimumab for pulmonary metastatic melanoma...
July 18, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28715649/excellent-response-to-anti-pd-1-therapy-in-a-patient-with-hepatocellular-carcinoma-case-report-and-review-of-literature
#6
Hirva Mamdani, Howard Wu, Bert H O'Neil, Amikar Sehdev
Hepatocellular carcinoma (HCC) is an aggressive cancer associated with high mortality worldwide. HCC develops in the setting of underlying cirrhosis due to chronic liver disease. Surgery is usually considered the treatment of choice for early disease; however, most patients have locally advanced or metastatic HCC at diagnosis in which case treatments are limited. Immune checkpoint blockade of programmed death receptor-1 (PD-1) pathway offers a potential treatment strategy based on the encouraging results of the phase I/II trial of nivolumab (Checkmate 040 trial)...
May 2017: Discovery Medicine
https://www.readbyqxmd.com/read/28713682/predictive-biomarkers-of-immunotherapy-for-non-small-cell-lung-cancer-results-from-an-experts-panel-meeting-of-the-italian-association-of-thoracic-oncology
#7
REVIEW
Cesare Gridelli, Andrea Ardizzoni, Massimo Barberis, Federico Cappuzzo, Francesca Casaluce, Romano Danesi, Giancarlo Troncone, Filippo De Marinis
Unleashing the potential of immune system to fight cancer has become one of the main promising treatment modalities for advanced non-small cell lung cancer (NSCLC). The knowledge of numerous factors that come into play in the cancer-immunity cycle provide a wide range of potential therapeutic targets, including monoclonal antibodies that inhibits the programmed death-1 (PD-1) checkpoint pathway. Over the last two years, nivolumab, pembrolizumab and atezolizumab received approval for treatment of pretreated advanced NSCLC, and more recently, immunotherapy with pembrolizumab is the new standard of care as first-line in patients with high levels of programmed death-ligand 1 (PD-L1) expression...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28711086/the-new-paradigm-of-systemic-therapies-for-metastatic-melanoma
#8
REVIEW
Virginia O Volpe, Daniel M Klufas, Upendra Hegde, Jane M Grant-Kels
New treatments for metastatic melanoma work through distinct mechanisms: enhancing the immune response and blocking cellular proliferation. Agents that enhance the immune response include ipilimumab, pembrolizumb, and nivolumab; agents that block cellular proliferation include vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, and selumetinib. The translational impact of laboratory discoveries has revolutionized management of metastatic melanoma and enhanced the prognosis of affected patients.
August 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28710099/nivolumab-plus-ipilimumab-has-antitumor-activity-in-metastatic-rcc
#9
(no author information available yet)
Nivolumab plus ipilimumab achieves durable responses and has manageable safety in metastatic RCC.
July 14, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28706158/significant-benefit-of-nivolumab-treating-pd-l1-positive-metastatic-pulmonary-carcinosarcoma-a-case-report-and-literature-review
#10
Zhe Zhang, Yishan Chen, Mingxia Ma, Junli Hao, Rui Ding, Lixin Han, Jiayun Zou, Lina Zhang, Qin Meng, Xiujuan Qu, Yunpeng Liu, Mingfang Zhao
Immunotherapy has recently become a new focus for the treatment of malignant tumors following the surgery, chemotherapy, radiotherapy, and molecular targeted therapy. Nivolumab, a human monoclonal antibody, is the first programmed cell death protein-1 (PD-1) inhibitor, which can prohibit the interaction of its ligand (PD-L1), restoring the immune response of T cells, and enhancing the recognition of tumor cells by the immune system.Pulmonary Carcinosarcoma is an uncommon but highly aggressive tumor type with a poor prognosis...
July 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28705024/medi-4736-durvalumab-in-non-small-cell-lung-cancer
#11
Arnaud Jeanson, Fabrice Barlesi
Immune checkpoint inhibitors (ICI) are now a therapeutic option for advanced non-small cell lung cancer (NSCLC) patients. ICI, such as the PD-1 inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced NSCLC. Other notable PD-L1 inhibitors under development include avelumab and durvalumab. Areas covered: This article reviews literature on durvalumab development, from the preclinical data to the results of phase III clinical trials, whether published or presented at international scientific conferences...
July 13, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28687567/correction-nods-for-atezolizumab-and-nivolumab-from-fda
#12
(no author information available yet)
No abstract text is available yet for this article.
July 7, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28685821/pd-1-pd-l1-inhibitors-in-haematological-malignancies-update-2017
#13
REVIEW
Tomas Jelinek, Jana Mihalyova, Michal Kascak, Juraj Duras, Roman Hajek
The introduction of PD-1/PD-L1 pathway inhibitors is an important landmark in solid oncology with unprecedented practice-changing activity in various types of solid tumours. Amongst haematological malignancies, PD-1/PD-L1 inhibitors have been successful, so far, only in the treatment of classical Hodgkin lymphoma, which typically exhibits an over-expression of PD-1 ligands (PD-L1, PD-L2) due to alterations in chromosome 9p24.1. Such positive outcomes led to the FDA approval of nivolumab use in relapsed Hodgkin lymphoma in 2016 as the first haematological indication...
July 6, 2017: Immunology
https://www.readbyqxmd.com/read/28684660/comparative-efficacy-and-safety-of-immune-checkpoint-inhibitor-related-therapies-for-advanced-melanoma-a-bayesian-network-analysis
#14
Xin Li, Junpeng Wang, Yun Yao, Lei Yang, Zhiqin Li, Cheng Yu, Peiyan Zhao, Yongli Yu, Liying Wang
OBJECTIVES: We aimed to compare and rank the effects of 9 immune checkpoint inhibitor-related therapies for treating advanced melanoma. METHODS: We searched Pubmed, Cochrane databases, Web of Science, and ClinicalTrials.gov for randomized controlled trials of the immune checkpoint inhibitor-related treatments for advanced melanoma. Analysis was done on a Bayesian framework. RESULTS: Twelve trials including 5413 patients were identified. Ipilimumab plus nivolumab, nivolumab, and pembrolizumab were significantly more efficacious for progression-free survival (PFS) than ipilimumab (hazard ratio [HR], 0...
July 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28682883/nivolumab-induced-myasthenia-gravis-in-a-patient-with-squamous-cell-lung-carcinoma-case-report
#15
Yu-Hsiu Chen, Feng-Cheng Liu, Chang-Hung Hsu, Chih-Feng Chian
RATIONALE: Nivolumab (Nivo) is an immune checkpoint inhibitor that has been used to treat advanced melanoma, nonsmall cell lung carcinoma, and renal cell carcinoma since 2015. Nivo is associated with several side effects, including hepatitis, pneumonitis, acute renal failure, endocrine disorder, and other immune-related adverse events. Here, we describe the case of a 65-year-old man with squamous cell lung carcinoma who developed myasthenia gravis (MG) after a third Nivo infusion. PATIENT CONCERNS: A 65-year-old man with advanced squamous cell lung carcinoma developed ptosis, diplopia, drop head, and general weakness 5 days after a third Nivo infusion...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28680957/health-related-quality-of-life-as-a-prognostic-measure-of-clinical-outcomes-in-renal-cell-carcinoma-a-review-of-the-checkmate-025-trial
#16
EDITORIAL
Marc-Oliver Grimm, Viktor Grünwald
The phase III, randomized, open-label CheckMate 025 study showed an overall survival benefit in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus. Here, we review the health-related quality of life (HRQoL) results of this trial, in which nivolumab was associated with significant improvements in HRQoL, with more patients having a clinically meaningful HRQoL improvement and a shorter time to onset of improvement compared with everolimus. Further exploratory analysis suggests a positive correlation between baseline HRQoL scores and overall survival...
2017: Oncology and Therapy
https://www.readbyqxmd.com/read/28679767/tumor-response-dynamics-of-advanced-non-small-cell-lung-cancer-patients-treated-with-pd-1-inhibitors-imaging-markers-for-treatment-outcome
#17
Mizuki Nishino, Suzanne E Dahlberg, Anika E Adeni, Christine Lydon, Hiroto Hatabu, Pasi A Janne, F Stephen Hodi, Mark M Awad
Purpose:  We evaluated tumor burden dynamics in advanced non-small-cell lung cancer (NSCLC) patients treated with commercial PD-1 inhibitors to identify imaging markers associated with improved overall survival (OS). <p>Experimental Design:  The study included 160 advanced NSCLC patients treated with commercial nivolumab or pembrolizumab monotherapy as a part of clinical care.  Tumor burden dynamics were studied for the association with OS.</p> <p>Results: Tumor burden change at best overall response (BOR) ranged from -100% to +278% (median: +3...
July 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28679408/partial-response-of-pulmonary-adenocarcinoma-with-symptomatic-brain-metastasis-to-nivolumab-plus-high-dose-oral-corticosteroid-a-case-report
#18
Hélène Pluchart, Julian Pinsolle, Julien Cohen, Gilbert R Ferretti, Pierrick Bedouch, Matteo Giaj Levra, Anne-Claire Toffart, Denis Moro-Sibilot
BACKGROUND: Nivolumab, a monoclonal antibody targeting the programmed death-1 receptor, is indicated in locally advanced or metastatic non-small cell lung cancer, with progression after platinum-based chemotherapy. Up-to-now, few data are available concerning brain activity of this treatment and concomitant use of corticosteroids. CASE PRESENTATION: A 64-year-old caucasian man with a pulmonary adenocarcinoma associated with brain metastases received four courses of nivolumab in concomitance with a high dose of corticosteroids for his neurologic symptoms...
July 6, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28679287/the-safety-of-nivolumab-for-the-treatment-of-metastatic-melanoma
#19
James Larkin, Aine O'Reilly
Nivolumab, a human IgG4 monoclonal antibody directed against PD-1, is a checkpoint inhibitor that is licenced in the treatment of metastatic melanoma either as a monotherapy or in combination with ipilimumab, a CTLA-4 inhibitor. The introduction of immune checkpoint inhibitors to the therapeutic landscape has dramatically altered outcomes in a proportion of patients with metastatic melanoma. Immune checkpoint inhibitors result in a toxicity profile that is distinct from that of chemotherapy or targeted therapy based on their immunomodulatory mechanism and similarly can result in patterns of response that are unique...
July 6, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28678991/nivolumab-therapy-for-treatment-related-vitiligo-in-a-patient-with-relapsed-metastatic-melanoma
#20
Yasuhiro Nakamura, Yukiko Teramoto, Yuri Asami, Taisuke Matsuya, Jun-Ichi Adachi, Ryo Nishikawa, Akifumi Yamamoto
No abstract text is available yet for this article.
July 5, 2017: JAMA Dermatology
keyword
keyword
9969
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"